Susan G. Hilsenbeck, Ph.D. - Publications
The articles are listed in chronological order, with the most recent publications at the top. You can download pdf files of many articles by clicking on the [PDF] text by each listing.
2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | Books/Chapters | Abstracts
2007
Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR, Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K, Mohsin S. Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2007 Apr 28; [Epub ahead of print]. [PDF]
Moraes RC, Zhang X, Harrington N, Fung JY, Wu MF, Hilsenbeck SG, Allred DC, Lewis MT. Constitutive activation of smoothened (Smo) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development 134(6):1234-1242, 2007. [PDF]
2006
Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res 66(24):12009-12018, 2006. [PDF]
Huang S, Podsypanina K, Chen Y, Cai W, Tsimelzon A, Hilsenbeck S, Li Y. Wnt-1 is dominant over Neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat 5(6):565-572, 2006. [PDF]
Ma X-J, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender C, Osborne CK, Allred DC, Erlander MG. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24:4611-4619, 2006. [PDF]
Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 12(17):5047-5054, 2006. [PDF]
Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66(16):8266-8273, 2006. [PDF]
Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107(4):696-704, 2006. [PDF]
Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM. Transcriptional profiling of mammary gland side population cells, Stem Cells 24:1065-1074, 2006. [PDF]
Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'connell P, Chang JC. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat 95:229-233, 2006. [PDF]
Martin M.D., Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 95:7-12, 2006. [PDF]
Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 8:R6, 2006. [PDF]
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the fifth international conference on recent advances and future directions in endocrine therapy for breast cancer: conference summary statement. Clin Cancer Res 12:997s-1000s, 2006. [PDF]
Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res 12:1013s-1018s, 2006. [PDF]
Hilsenbeck SG, Osborne CK. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res 12:1049s-1055s, 2006. [PDF]
Bourgogne A, Hilsenbeck SG, Dunny GM, Murray BE. Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the fsr system of enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol 188:2875-2884, 2006. [PDF]
Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 66:5950-5959, 2006. [PDF]
Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Borwn PH. The AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol 2006 Apr 4 [PDF].
2005
DeNardo DG, Kim H-T, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrin 19:362-378, 2005. [PDF]
Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89:173-178, 2005. [PDF]
Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, DiGiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23(6):2460-2468, 2005. [PDF]
Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the management and treatment of breast cancer. Br J Cancer 92:618-624, 2005. [PDF]
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Guiterrez MC, Tham Y-L, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell PO. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177, 2005. [PDF]
Chen DT, Rosenstein DL, Muthappan P, Hilsenbeck SG, Miller FG, Emanuel EJ, Wendler D. Research with stored biological samples: what do research participants want? Arch Intern Med 165:652-655, 2005. [PDF]
Kong G, Kim HT, Wu K, Denardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65(8):3462-3469, 2005 . [PDF]
Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 23:4687-4694, 2005. [PDF]
Jeong J-W, Lee KY, Kwak I, White LD, Hilsenbeck, SG, Lydon JP, DeMayo FJ. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology 146(8):3490-3505, 2005. [PDF]
Lu C, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 24:6516-6524, 2005. [PDF]
Osborne CK, Schiff R, Arpino G, Lee A, Hilsenbeck SG. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 14(6):458-465, 2005. [Abstract]
Tham Y-L, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 94:279-284, 2005. [PDF]
2004
Drysdale M, Bourgogne A, Hilsenbeck SG, Koehler TM. atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol 186(2):307-315, 2004. [PDF]
Han ES, Wu Y, McCarter R, Nelson JF, Richardson A, Hilsenbeck SG. Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high density oligonucleotide array experiments. J Gerontol Biol Sci Med Sci 59:B306-B315, 2004. [Abstract]
Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SAW. Breast cancer patients with progesterone receptor PR-A-Rich tumors have poorer disease-free survival rates. Clin Cancer Res 10:2751-2760, 2004. [PDF]
Lu C, Mohsin SK , Hilsenbeck S, Wakeling A, Brown PH. Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 96:715-717, 2004. [PDF]
Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH, Lee EY. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 64(10):3525-3532, 2004. [PDF]
Fuqua SAW, Chang JC, Hilsenbeck SG. Genomic approaches to understanding and treating breast cancer. Breast Dis 19:35-46, 2004. [Abstract]
Kalidas M, Hilsenbeck S, Brown P. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst 96:1731-1733, 2004. [PDF]
2003
Osborne CK, BardouV, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361, 2003. [PDF]
Bourgogne A, Drysdale M, Hilsenbeck SG, Perterson SN, Koehler TM. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun 71:2736-2743, 2003. [PDF]
Liu Q, Hilsenbeck S, Gazitt, Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9 and synergy with APO2/TRAIL. Blood 15, 101:4078-4087, 2003. [PDF]
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MG, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P. Gene expression profiling predicts therapeutic response to docetaxel (Taxotere™) in breast cancer patients. Lancet 2003 [PDF]
Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 95:1825-1833, 2003. [PDF]
Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Guiterrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4(5):348-53, 2003. [Abstract]
2002
Wu K, Kim H-T, Rodriguez JL, Hilsenbeck SG, Mohsin SK, Xu X-C, Lamph WW, Kuhn JG, Green JE, Brown PH. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 11:467-474, 2002. [PDF]
Berry DA, Iversen Jr ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701-2712, 2002. [PDF]
Sivaraman L, Gay J, Hilsenbeck SG, Shine HD, Conneely OM, Medina D, O’Malley BW. Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis. Breast Cancer Res Treat 73:75-83, 2002. [PDF]
Lawrence VA, Hilsenbeck SG, Noveck H, Poses RM, Carson JL. Medical complications and outcomes after hip fracture repair. Arch Int Med 162(18):2053-2057, 2002. [PDF]
Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim H-T, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Inhibition of AP-1 transcription factor causes global signal Transduction blockade and inhibits breast cancer growth. Oncogene 21:7680-7689, 2002. [PDF]
deGraffenried LA, Hilsenbeck SG, Fuqua SA. Sp1 is essential for estrogen receptor alpha gene transcription. J Ster Biochem Mol Biol 82:7-18, 2002. [PDF]
Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 62:6376-6380, 2002. [PDF]
2001
Hilsenbeck SG. Quality in cancer registries – where have we been and where are we going? Guest Editorial. J Registry Mgmt 28:22-23, 2001.
Hansen RK, Parra I, Hilsenbeck SG, Himelstein B, Fuqua SAW. Hsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes. Biochem Biophys Res Commun. 282(1):186-193, 2001. [PDF]
Han E-S, Hilsenbeck SG. Array-based gene expression profiling to study aging. Mech Ageing Dev 122(10):999-1018, 2001. [PDF]
Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC. Pathological features and brca1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 7(6):1739-1742, 2001. [PDF]
Leach CT, Koo FC, Kuhls TL, Hilsenbeck SG, Jenson HB. Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors. Am J Trop Med Hyg 62(5):656-661, 2001. [PDF]
Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 20(22):2771-2780, 2001. [PDF]
Sivaraman L, Hilsenbeck SG, Zhong L, Gay J, Conneely OM, Medina D, O’Malley BW. Early exposure of the rat mammary gland to estrogen and progesterone blocks colocalization of ER expression and proliferation. J Endocrinol 171(1):75-83, 2001. [PDF]
Medina D, Sivaraman L, Hilsenbeck SG, Conneely O, Ginger M, Rosen J, O,Malley BW. Mechanisms of hormonal prevention of breast cancer. Ann NY Acad Sci 952:23-35, 2001. [PDF]
2000
Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18(9):1906-1913, 2000. [PDF]
Fernandes NF, Schwesinger WH, Hilsenbeck SG, Gross GW, Bay MK, Sirinek KR, Schenker S. Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl 6(3):340-344, 2000. [PDF]
Fuqua SAW, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O’Connell P, Allred DC. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60:4026-4029, 2000. [PDF]
Weitman S, Barrera H, Moore R, Gonzalez C, Marty J, Hilsenbeck S, MacDonald JR, Waters SJ, Von Hoff D. MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol 22:306-314, 2000. [Full Text]
Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan K-W. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant 26:601-605, 2000. [PDF]
Han E-S, Hilsenbeck SG, Richardson AG, Nelson JF. cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction. Mech Ageing Dev 115:157-174, 2000. [PDF]
Wu K, Kim HT, Rodriguez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res 6:3696-3704, 2000. [PDF]
Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 92(23):1926-1934, 2000. [PDF]
Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV 522 lung carcinoma xenografts model. Eur J Cancer 36(18):2430-2436, 2000. [PDF]
1999
Diab SG, Hilsenbeck SG, Izbicka E, Weitman S, Von Hoff DD. Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. Anti-Cancer Drugs, 10:303-307, 1999. [Abstract]
Hilsenbeck SG, Von Hoff DD. Editorial. Measure once or twice—does it really matter? J Natl Cancer Inst 91(6):494-495, 1999. [PDF]
Hilsenbeck SG, Friedrichs WG, Schiff R, O' Connell P, Hansen R, Osborne CK, Fuqua SAW. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst 91:453-459, 1999. [PDF]
Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59:1049-1053, 1999. [PDF]
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13(5):787-796, 1999. [PDF]
Weitman S, Mangold G, Marty J, Dexter D, Hilsenbeck SG, Rake J, Juniewicz P, Von Hoff D. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol 43(5):402-408, 1999. [PDF]
Britten CD, Izbicka E, Hilsenbeck SG, Lawrence R, Davidson K, Cerna C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DD. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 44(2):105-10, 1999. [PDF]
Leach CT, Koo FC, Hilsenbeck SG, Jenson HB. The epidemiology of viral hepatitis in children in South Texas: Increased prevalence of hepatitis A along the Texas-Mexico border. J Infect Dis 180(2):509-513, 1999. [PDF]
Cody JD, Ghidoni PD, DuPont BR, Hale DE, Hilsenbeck SG, Stratton RF, Hoffman DS, Muller S, Schaub RL, Leach RJ, Kaye CI. Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet 85(5):455-462, 1999. [PDF]
Hansen RK, Parra I, Lemiux P, Oesterreich S, Hilsenbeck SG, Fuqua SAW. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56(2):187-196, 1999. [PDF]
O’Connell P, Fischbach K, Hilsenbeck SG, Mohsin SK, Fuqua SAW, Clark GM, Osborne CK, Allred DC. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst 91(16):1391-7, 1999. [PDF]
Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17(8):2334-2340, 1999. [PDF]
Lichtenstein MJ, Marshall C, Pruski L, Blalock L, Lee S, Murphy D, Hilsenbeck S. Positively Aging: Choices and changes creating interdisciplinary middle school teaching materials using examples from Geriatrics and Gerontology. Educational Gerontology 25:555-569, 1999. [Abstract]
Hilsenbeck SG, Von Hoff DD. RESPONSE: re measure one or twice-does it really matter? J Natl Cancer Inst 91(20):1780A-1781, 1999. [PDF]
Books/Chapters
Hanauske A-R, Hilsenbeck SG, Von Hoff DD. The human tumor-cloning assay. In Schilsky RL, Milano GA, Ratain MJ (eds), Principles of Antineoplastic Drug Development and Pharmacology. New York, Marcel Dekker, Inc, 1996, 15-27.
Hanauske A-R, Hilsenbeck SG, Von Hoff DD. Human tumor screening. In Teicher B, (ed). Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. Totowa, NJ, Humana Press, Inc. 1997, 43-56
Abstracts
Leach CT, Koo FC, Hilsenbeck SG, Jenson HB. Epidemiology of Cryptosporidium parvum in three groups of children in South Texas. Society for Pediatric Research, Pediatric Academic Societies' 1999 Annual Meeting, San Francisco, CA, May 1-4, 1999.
Hilsenbeck SG, Schiff R, Friedrich W, O'Connell P, Osborne CK, Hansen RK, Fuqua SAW. Statistical analysis of high-density gene arrays. Proc 21st Annual San Antonio Breast Cancer Symposium (Abstr 9), 1998.
Schiff R, Ahotupa M, Reddy P, Coronado E, Hilsenbeck S, Fuqua SAW, Herrera R, Brown PH, Lawrence R, Deneke S, Osborne CK. Tamoxifen-stimulated breast tumor growth is associated with cellular oxidative stress and increased JNK activity. Proc 21st Annual San Antonio Breast Cancer Symposium (Abstr 163), 1998.
O'Connell P, Fischbach K, Hilsenbeck S, Fuqua SAW, Mohsin SK, Martin M, Clark GM, Osborne CK, Allred DC. Loss of heterozygosity at D14S62 is inversely correlated with metastatic potential. Proc 21st Annual San Antonio Breast Cancer Symposium (Abstr 176), 1998.
Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck S, Fuqua SAW. Overexpression of hsp27 inhibits drug-induced apoptosis in breast cancer cells. Proc 21st Annual San Antonio Breast Cancer Symposium (Abstr 263), 1998.
Wu K, Kim H-T, Tin-U CK, Yang L-M, Hilsenbeck S, Munoz-Medellin D, Lamph W, Gottardis M, Brown PH. Receptor-selective retinoids suppress mammary tumorigenesis in C3(1)-SV-40 T-antigen transgenic mice. Proc 21st Annual San Antonio Breast Cancer Symposium (Abstr 427), 1998.
Wu K, Tin-U CK, Hilsenbeck SG, Bischoff ED, Lamph WW, Blumberg B, Brown PH. The RXR-selective retinoid LGD1069, activates RXR-and PPAR- dependent pathways in breast cells. Proc 22nd Annual San Antonio Breast Cancer Symposium (Abstr 174), 1999.
Ludes-Meyers JH, Muñoz-Medelin DM, Hilsenbeck SG, Brown PH. Growth factor-induced proliferation of breast cells requires AP-1 transactivation activity. Proc 22nd Annual San Antonio Breast Cancer Symposium (Abstr 465), 1999.
Mohsin SK, Hilsenbeck SG, Osborne CK, Allred DC. ER and PGR in premalignant breast lesions and normal. Proc 22nd Annual San Antonio Breast Cancer Symposium (Abstr 480), 1999.
Allred DC, Hilsenbeck SG, Mohsin SK, Clark GM, Osborne CK. ER and PGR status of normal epithelium and premalignant lesions are not prognostic for breast cancer. Proc 22nd Annual San Antonio Breast Cancer Symposium (Abstr 481), 1999.
Hansen RK, Parra I, Hilsenbeck SG, Himelstein B, Fuqua SAW. Hsp27-induced matrix metalloproteinae-9 expression inhuman breast cancer cells is influenced by the SRC tyrosine protein kinase YES. Proc Am Assoc Cancer Res 41:860, 2000.
Wu K, Tin-U CK, Hilsenbeck SG, Bischoff ED, Lamph WW, Brown PH. The RXR-selective retinoids inhibit breast cell growth by inducing a G1 cell cycle block. Proc Am Assoc Cancer Res 41:1501, 2000.
Hopp TA, Hilsenbeck S, Mohsin S, O’Connell P, Allred DC, Fuqua SAW. A hypersensitive estrogen receptor ? protein in premalignant breast lesions. Breast Cancer Res Treat 64:1 (Abstr 31), 2000.
Chang J, O’Connell P, Hilsenbeck SG. Feasibility of measuring gene expression patterns using core biopsies of human primary breast cancers and cDNA microarray technology. Breast Cancer Res Treat 64:1 (Abstr 280), 2000.
Immaneni A, Li Z, Hilsenbeck SG, Allred DC, O’Connell, P. Can gene expression pattern analysis predict recurrence in node-negative breast cancer? Breast Cancer Res Treat 64:1 (Abstr 421), 2000.
Hilsenbeck SG. Interpreting clinical trails: a review, part II. American Society of Clinical Oncology, Thirty-Seventh Annual Meeting, San Francisco, CA, May 12-15, 2001 (pg 364-366).
Martin M.D., Allred DC, Clark GM, Mohsin S, Hilsenbeck SG, Osborne CK, O'Connell P. Mapping and characterization of a candidate metastasis gene on chromosome 14q. Proc Am Assoc Cancer Res 42:514 (abstract 2765), 2001.
Hopp TA, Allred DC, Mohsin S, Hilsenbeck SG, Nawaz Z, Pestell RG, Fuqua SAW. A hypersensitive estrogen receptor ? protein in breast cancer. Proc Am Assoc Cancer Res 42:896 (abstract 4806), 2001.
Azizzadeh A, Kelemen PR, Hilsenbeck SG, Wilson LL, Lucci A. Recovery time following sentinel lymph node dissection vs complete axillary dissection in patients with breast cancer. Submitted to Southwest Surgical Society Meeting, Coronado, CA, April, 2002.
Wooten EC, Chang J, Hilsenbeck SG, Tsimelzon A, Mohsin S, O’Connell P. Gene expression profiles from breast cancer core biopsies predict therapeutic response. Proc Am Assoc Cancer Res 43:450 (abstract 2238), 2002.
Li Z, Tsimelzon A, Immaneni A, Mohsin SK, Hilsenbeck SG, Clark G, Fuqua SAW, Osborne CK, O’Connell P, Allred DC. A cDNA microarray study comparing noninvasive and invasive human breast cancer. Proc Am Assoc Cancer Res 43:901-902 (abstract 4471), 2002.
Chang JCN, Wooten EC, Tsimelzon A, Hilsenbeck SG, Lewis M, Elledge R, Osborne CK, Gutierrez MC, Allred DC, O'Connell PO. Gene expression patterns for de novo and acquired docetaxel resistance in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 22:32, Abstr 32, 2003.
Chen DT, Rosenstein DL, Miller FG, Hilsenbeck SG, Muthappan G, Emanuel EJ, Wendler D. Most research subjects permit use of biological samples in future research. Proc Am Soc Clin Oncol 22:524, Abstr 2110, 2003.